Preclinical antitumor activity of S-222611, an oral reversible tyrosine kinase inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor 2.
Bottom Line: In addition, S-222611 showed potent antitumor activity over lapatinib in a variety of xenograft models.In evaluations with two patient-oriented models, the intrafemoral implantation model and the intracranial implantation model, S-222611 exhibited excellent activity and could be effective against bone and brain metastasis.Considering the safer profile than for irreversible inhibitors, S-222611 could be an important option in future cancer therapy.
Affiliation: Discovery Research Laboratory for Innovative Frontier Medicines, Shionogi & Co., Ltd., Toyonaka, Osaka, Japan.Show MeSH
Related in: MedlinePlus
Mentions: We evaluated S-222611 in patient-oriented models. Because bone metastasis is observed in more than 80% of advanced breast cancer patients with significant morbidity, we examined S-222611 using a model of luciferase-expressing human breast cancer cells implanted into the femur of nude mice.(30) S-222611 showed approximately four times more potent activity than lapatinib and completely inhibited the growth of cancer cells at 50 mg/kg (Fig. 3a,b).
Affiliation: Discovery Research Laboratory for Innovative Frontier Medicines, Shionogi & Co., Ltd., Toyonaka, Osaka, Japan.